Fig. 3: In vivo assessment of efficacy. | Nature Communications

Fig. 3: In vivo assessment of efficacy.

From: Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance

Fig. 3

a Dose-dependent anti-tumor effect of mProIFNa4-Fc. C57BL/6 J mice were s.c. inoculated with 5 × 105 B16 tumor cells and i.p. treated with 0, 0.01, 0.1, or 1 nmol of fusion protein on day 7, 10, and 13 (n = 10 animals). Tumor volume was shown. b Cleavable linker dependent anti-tumor effect of mProIFNa4-Fc. C57BL/6 J mice were s.c. inoculated with 5 × 105 B16 tumor cells and i.p. treated with 1 nmol of hIg, mProIFNa4-Fc without cleavable substrate (Non-sub), or mProIFNa4-Fc on day 8 and 11 (n = 8 animals). Tumor volume was shown. c, d C57BL/6 J mice were s.c. inoculated with 5 × 105 B16 tumor cells and i.p. treated with 1 nmol of hIg, mIFNa4-Fc, or mProIFNa4-Fc, on day 8, 11, and 14 (n = 10 animals). Tumor growth (c) and body weight (d) were shown. e, f C57BL/6 J mice were s.c. inoculated with 1 × 106 LLC tumor cells and i.p. treated with 1 nmol of hIg, mIFNa4-Fc, or mProIFNa4-Fc, on day 12, 15, and 18 (n = 9 animals). Tumor growth (e) and body weight (f) were shown. g, h C57BL/6 J mice were s.c. inoculated with 1 × 106 MC38 tumor cells and i.p. treated with 1 nmol of hIg, mIFNa4-Fc, or mProIFNa4-Fc, on day 9, 12, and 15 (n = 9 animals). Tumor growth (g) and body weight (h) were shown. Data are reported as mean ± s.e.m. Two-way ANOVA was performed to calculate p-values. Source data are provided as a Source Data file.

Back to article page